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Heart failure is a systemic disorder characterised by
tissue hypoxia and secondary organ dysfunction which
occurs in response to various myocardial insults that
include ischaemia, viral infections, and toxins. In
addition to maladaptive neurohumoral activation, heart
failure is associated with an inflammatory state that
appears to have a detrimental effect on cardiac function
and prognosis. This has led to the suggestion that
anti-inflammatory interventions may have therapeutic
potential in the symptomatic and prognostic treatment of
patients with heart failure. This review considers the role
of inhibition of the cytokine tumour necrosis factor α in
the treatment of heart failure.
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Tumour necrosis factor α (TNFα) is a 157amino acid cytokine that is produced inresponse to inflammatory or infectious
stimuli by macrophages, lymphocytes, neu-
trophils, and structural cells including fibroblasts
and smooth muscle cells. It is one of many
immunological mediators involved in critical
aspects of cell function including the response to
injury, inflammation, and death through necrosis
or apoptosis. We describe the rationale for, and
results of, recent clinical trials of TNFα blockade
in patients with chronic heart failure.
TUMOUR NECROSIS FACTOR α: A
PROINFLAMMATORY PLEIOTROPIC
CYTOKINE
TNFα acts through two transmembrane recep-
tors, TNFα receptor (TNFR) types 1 and 2. When
stimulated, these receptors interact with a variety
of cell signal pathways increasing expression of
proinflammatory cytokines, such as interleukin 6,
and regulating cell survival, growth, and apop-
totic death. However, the response to TNFα is
non-uniform and critically depends upon the cell
type, the state of cellular activation, and the local
concentrations of the cytokine (table 1). For
example, TNFα may promote cell survival and
proinflammatory gene expression, and yet in the
presence of transcription factor blockade the
same stimulus may drive the cell towards apopto-
sis and death. This contextual dependence of
TNFα action is not only restricted to in vitro
observations. Infusion of TNFα in healthy hu-
mans produces vasoconstriction1 and procoagu-
lant effects,2 while in volunteers injected with
endotoxin, high TNFα concentrations are associ-
ated with hypotension, increased vascular perme-
ability, and myocardial depression.3 Thus the
environment within which the TNFα signal is
received is crucial and may explain some of the
conflicting evidence regarding its actions on
cardiomyocyte function and survival.
TUMOUR NECROSIS FACTOR α AND
HEART FAILURE
Cytokines have been implicated in the syndrome of
chronic heart failure for over a decade.4 Levine and
colleagues5 first described raised plasma TNFα
concentrations in non-septic patients with chronic
heart failure. Subsequent studies showed compar-
able elevations of two other cytokines, interleukin
6 and interleukin 1β (IL-1β),6 and a direct correla-
tion between plasma TNFα concentrations and the
degree of heart failure, as assessed by functional
heart failure classification7 (fig 1). The increase in
plasma TNFα concentrations appears to be most
striking in those patients with generalised body
wasting or cardiac cachexia—a clinical feature that
is particularly associated with a poor prognosis.8 9
However, plasma TNFα concentrations are not
necessarily representative of the functional activity
of the cytokine. Localised myocardial production of
TNFα has been demonstrated within the failing
heart, suggesting that there may be significant
additional autocrine or paracrine actions.10
What drives TNFα production in patients
with heart failure?
Inflammation contributes to the development
and progression of heart failure,11 and markers of
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Abbreviations: ATTACH, anti-TNF alpha therapy against
chronic heart failure; IL-1β, interleukin 1β; iNOS, inducible
nitric oxide synthase; NF-κB, nuclear factor κB;
RENAISSANCE, ramdomized etanercept North American
strategy to study antagonism of cytokines; RECOVER,
research into etanercept antagonism in ventricular
dysfunction; TNFα, tumour necrosis factor α; TNFR, tumour
necrosis factor α receptor
Table 1 Contrasting actions of tumour
necrosis factor α in patients with heart
failure
Adaptive Maladaptive
Myocardial hibernation Reduced myocyte contractility
Inhibition of apoptosis Apoptosis
Hypertrophy Fibrosis
Leucocyte recruitment
Impaired vascular function
Induction of inflammation
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inflammation, such as C reactive protein, are independent
predictors of the presence of heart failure.12 TNFα production
represents a phylogenetically conserved response to cellular
stress, inflammation, and injury. The specific stimuli responsi-
ble for increased TNFα production in patients with heart fail-
ure have not been elucidated but there are several potential
candidates.
Endotoxin, a component of the outer coat of Gram negative
bacteria, is a potent stimulus for macrophage TNFα produc-
tion and it is intriguing that non-septic patients with decom-
pensated failure and oedema are more likely to have subclini-
cal endotoxaemia.13 Indeed, resolution of oedema with
diuretic treatment is associated with the disappearance of
endotoxin, leading to a proposal that oedematous bowel is
more permeable to bacteria.
Plasma markers of oxidative stress are increased in patients
with heart failure.14 15 The tissue origins of these markers have
not been elucidated, although poorly perfused peripheral
muscles and the failing myocardium are likely candidates.
TNFα and angiotensin II stimulate free radical production in
a variety of cell types16 and contribute to oxidative stress in
patients with heart failure. The reactive oxygen species
produced may exert their effect through the nuclear factor κB
(NF-κB) system, a ubiquitous transcription factor responsive
to oxidative stress.17 Active NF-κB is present within failing
cardiomyocytes, and its activity correlates inversely with the
improvement associated with a left ventricular assist device.18
It interacts with the regulatory elements of many genes con-
cerned with response to injury, including TNFα itself and
inducible nitric oxide synthase (iNOS). The NF-κB transcrip-
tion factor system may be one point of molecular convergence
for diverse pathologies—including ischaemia, haemodynamic
overload,19 and viral infection—that result in increased TNFα
expression in patients with cardiac failure.
ADVERSE CARDIAC EFFECTS OF TNFα
Myocyte contractility
TNFα impairs myocyte contractility. It has been shown to have
negative inotropic activity measured both by left ventricular
pressure–volume curves and isolated cardiac myocyte frac-
tional shortening.20 This results from a decrease in the voltage
dependent calcium current responsible for depolarisation of
the myocyte and the release of sarcoplasmic reticular calcium
stores. Although uncoupling of β adrenoceptors from their
intracellular signalling pathways may have a role,21 this effect
appears to be mediated, at least in part, through mechanisms
that involve increased nitric oxide synthesis.
Nitric oxide has negative inotropic effects that include the
inhibition of creatine kinase22 and the downregulation of
mitochondrial respiration.23 TNFα increases the expression
and synthesis of iNOS that has been described in the myocar-
dium of patients with heart failure.24 25 Nitric oxide synthase
inhibition is able to reverse the TNFα mediated reductions in
isolated ventricular papillary muscle tension.26 However, these
findings are not universal, and Mann’s group failed to demon-
strate reversal of myocardial depression with a nitric oxide
synthase inhibitor following TNFα infusions in rats.27
Myocardial fibrosis and apoptosis
Transgenic mice which selectively overexpress TNFα in
cardiomyocytes have a phenotype of myocarditis with
interstitial infiltrates, four chamber dilatation, and compensa-
tory myocyte hypertrophy.28 There are striking parallels
between these transgenic murine TNFα hearts and the
myocardium of patients with chronic heart failure. At the cel-
lular level, transgenic hearts have patterns of gene expression
that are particular to failing myocardium. These include reac-
tivation of the fetal gene programme within the ventricle (for
example, atrial natriuretic factor) and an increase in metallo-
protease activity that facilitates extracellular matrix remodel-
ling. Interstitial cell (and to a lesser extent myocyte) apoptosis
is also a consistent feature of the transgenic myocardium.29
The transgenic models may represent one extreme of
sustained or excessive production of TNFα. The generation of
TNFα is initially compensatory and sufficient to promote the
hypertrophic growth of cardiac myocytes and to induce the
expression of cytoprotective antiapoptotic factors in a variety
of cell types.30 This protective role is borne out by the observa-
tion that TNFR-1/TNFR-2 deficient mice have an increased
susceptibility to cardiomyocyte apoptosis following myocar-
dial infarction.31 These studies illustrate the potentially impor-
tant and contrasting roles of TNFα as a negative inotrope fol-
lowing prolonged expression in the failing myocardium, while
paradoxically acting as a protective agent limiting myocyte
death during acute ischaemia and infarction.
THERAPEUTIC INHIBITION OF TNFα IN PATIENTS
WITH HEART FAILURE
Rationale
If cytokine production represents a maladaptive response to
cellular injury leading to further organ dysfunction (compare
the neurohormonal activation occurring in heart failure),
then inhibition of TNFα may be beneficial. Several lines of
evidence suggest this may be the case.
Animal models
Anti-TNFα treatments were first assessed in animal models of
septicaemia. Infusion of recombinant TNFR-2 fragments pro-
tected rabbits from bacterial endotoxin induced septic shock.
This was associated with an improvement in cardiac output
and arterial pressure, indicating that TNFα blockade was
effective in reversing the depressed myocardial contractility
and vascular tone associated with this condition.32 Subsequent
studies in the TNFα transgenic mouse have shown that
neutralising fragments of the TNFα receptor attenuate certain
features of the heart failure phenotype. Interstitial infiltrates
were reduced and matrix metalloprotease concentrations
returned to normal, although hypertrophy and fibrosis
Figure 1 Relative (percentage)
plasma tumour necrosis factor α
concentrations according to New
York Heart Association (NYHA)
classification of symptoms (left panel;
data from Torre-Amione and
colleagues10) and the presence of
cachexia (right panel; data from
Anker and colleagues9) in patients
with heart failure.
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persisted.33 Both these septic and transgenic animal models
are characterised by myocardial depression in the context of
extreme TNFα production. Little work has been done on TNFα
blockade in heart failure models more relevant to human dis-
ease, although one group has shown an improvement in car-
diac function following ischaemia-reperfusion injury in rabbit
hearts treated with neutralising TNFα antibody.34
Clinical observational studies
A progressive increase in plasma TNFα with increasing sever-
ity of decompensated heart failure and a fall with therapeutic
intervention provides indirect evidence that strategies to
reduce TNFα signalling may be beneficial. Two further obser-
vations lend support to this view. High intracellular concentra-
tions of adenosine would be expected to reduce TNFα produc-
tion, and a mutation in the adenosine monophosphate
deaminase-1 gene, which slows adenosine metabolism, is
associated with improved survival following symptom onset
in patients with heart failure.35 Second, phosphodiesterase
inhibitors can also serve as inhibitors of TNFα production, and
the phosphodiesterase inhibitor pentoxyfilline significantly
improved symptoms and left ventricular ejection fraction in
patients with idiopathic dilated cardiomyopathy over a period
of six months.36 However, there are several potential alterna-
tive explanations for these clinical observations and it is
unclear whether any of these effects are mediated through
TNFα. Moreover, all previous clinical experience with the pro-
longed use of phosphodiesterase inhibitors, such as milrinone,
suggests that their positive inotropic activity worsens long
term survival.
Therapeutic agents
The favourable results of anticytokine treatment in other
inflammatory diseases37 have paved the way for trials of TNFα
blockade in patients with heart failure. Two antagonists that
bind and neutralise circulating TNFα are currently licensed
and have been successfully used in the treatment of rheuma-
toid arthritis and inflammatory bowel disease. Etanercept is a
fusion protein that employs a TNFR-2 fragment to recognise
circulating TNFα. It is effective in reducing markers of acute
inflammation, improving functional scores, and, importantly,
slowing progression of joint damage in patients with severe
rheumatoid arthritis in comparison with methotrexate.38 The
treatment remains effective and well tolerated during long
term administration and follow up.
Another strategy to inhibit cytokine signalling is the use of
neutralising monoclonal antibodies, although potential draw-
backs include direct activation of the complement system
leading to cell lysis and loss of efficacy with the development
of host antibodies. Analogous to abciximab, infliximab is a
monoclonal antibody that has been raised in mice with
neutralising activity against human TNFα. In order to reduce
the immunogenicity of this mouse protein, a chimeric
construct has been produced with segments of the protein
replaced with human counterparts. This treatment has proven
efficacy in patients with rheumatoid arthritis39 and inflamma-
tory bowel disease,37 and early clinical trials suggest it may
have a therapeutic role in patients with severe psoriasis.40
As the use of etanercept and infliximab has increased, so
have reports of undesirable side effects relating to immuno-
suppression, including invasive pulmonary aspergillosis,41
aseptic meningitis,42 and in particular the reactivation of
tuberculosis with infliximab. Patients should be screened for
latent tuberculosis infection before receiving infliximab, and
the occurrence of rare but serious side effects relating to
immunosuppression may limit the widespread applicability of
both these treatments to heart failure populations.
Early clinical experience in heart failure
Early trials of TNFα blockade in patients with heart failure
were encouraging. A pilot double blind randomised controlled
trial of etanercept, given as a single intravenous infusion, led
to significant increases in quality of life scores, six minute
walk distance, and ejection fraction in 18 patients with mod-
erately severe heart failure.43 Positive effects were only seen in
higher dose groups and a follow up study examined the effects
of prolonged antagonism with twice weekly subcutaneous
doses given for three months. The treatment was well
tolerated and again significant dose dependent improvements
in functional status and ventricular function were reported,
although the numbers were small (n = 47).44 Etanercept also
appears to correct the impaired endothelium dependent
vasodilatation in patients with heart failure, an effect that was
proportional to the plasma TNFα concentrations.45 However,
this initial promise was not borne out by two larger trials
(RECOVER and RENAISSANCE) that randomised over 1500
patients with NYHA grade II–IV heart failure in Europe and
North America, respectively. Last year, both trials were stopped
early because of the apparent futility of the treatment on an
interim analysis, with little likelihood of any benefit in terms
of symptoms, hospital admissions, or deaths. The complete
findings of these studies have yet to be published (table 2).
There has been only one small scale phase II trial of inflixi-
mab in patients with heart failure. The ATTACH trial recruited
150 patients with NYHA grade III–IV heart failure who were
randomised to placebo, low dose infliximab, and high dose
infliximab. This trial was also terminated early owing to an
apparent excess of hospital admissions and deaths, particu-
larly in patients receiving the higher dose.
Table 2 Recent trials of anti-tumour necrosis factor α treatment in patients with heart failure
Trial Design Outcome Published
Deswal et al Randomised double blind multidose pilot study of
etanercept in 18 patients with NYHA III heart failure
Etanercept was well tolerated and higher doses were
associated with significant improvements in quality of
life scores, 6 minute walk test, and left ventricular
ejection fraction
Yes43
Bozkurt et al Randomised double blind multidose pilot study of
etanercept in 47 patients with NYHA III–IV heart
failure
Etanercept was well tolerated with a significant
improvement in echocardiographic measures of left
ventricular function and a weak non-significant
(p=0.20) trend towards improvement in the combined
clinical end point
Yes44
RENAISSANCE and RECOVER North American and European limbs of a randomised
controlled trial examining two dosage regimes of
etanercept in 1500 patients with NYHA II–IV heart
failure and an ejection fraction <30%
Terminated early owing to futility, with no likelihood
of treatment benefit in the primary composite end
point of NYHA class, patient global assessment,
hospital admission, and death
No
ATTACH A pilot randomised controlled trial evaluating
infliximab in 150 patients with stable NYHA III–IV
heart failure, ejection fraction <35%, and no
concurrent infections
No difference in clinical status at 14 weeks with no
benefit at 28 weeks; a trend towards worsening
clinical status in the treatment group
No
NYHA, New York Heart Association classification of heart failure.
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FUTURE PERSPECTIVES
The evidence implicating TNFα and other cytokines in the
pathogenesis of heart failure is compelling. Clinical trials may
have been considered premature, given that the mechanisms
through which TNFα blockade could be beneficial are
unknown. The potential adverse effects of this novel treatment
are of concern, and the cytoprotective properties of TNFα may
be more important to certain categories of patients with heart
failure who may deteriorate following TNFα blockade. The
cost of long term administration and the possibility of side
effects from immunosuppression and hypersensitivity to these
agents are further problems that need to be addressed.
Clinical trials of TNFα blockade have failed to produce the
expected benefits in a large non-selective population of
patients with stable heart failure. Selected patient populations
with certain TNFα promoter polymorphisms may be predis-
posed to TNFα induced ventricular dysfunction. Future
anti-TNFα trials may be able to target patients with suscepti-
ble genotypes, and a recent study demonstrated overrepresen-
tation of the TNFα2 allele—a promoter polymorphism associ-
ated with increased inducible transcription of TNFα—in
patients with non-ischaemic left ventricular dysfunction.46
Generation of inflammatory mediators is a secondary event
in most cases of heart failure, and the balance of maladaptive
versus adaptive effects may change following disease progres-
sion or during acute exacerbations. It may be that differences
in the aetiology of heart failure are important, and future
research should focus on dissecting out the critical pathways
mediating ventricular dysfunction and determining which
patients may benefit most. It should also be remembered that
the inflammatory response to heart failure is associated with
the release of many cytokines and not just TNFα. For example,
IL-1β is a cytokine with similar signalling properties to TNFα,
is produced by cardiomyocytes, and is also increased in heart
failure. The deleterious actions of IL-1β will not be amelio-
rated by anti-TNFα treatment and this may contribute to
treatment failure.47 Alternative anti-inflammatory or anticy-
tokine treatments, used alone or in combination, now need to
be explored.
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IMAGES IN CARDIOLOGY.............................................................................
A novel form of spontaneous coronary vasospasm: bead-like vasospasm in an elderly man
A73 year old man presented with anginal chest pain and dyspnoeaat rest in the morning. Echocardiography showed moderatemitral regurgitation and normal left ventricular wall motion.
Coronary angiography revealed spontaneous tandem vasospasm,
which looked like beads, in the first diagonal branch of the left ante-
rior descending artery, but no significant spastic or organic stenosis in
other segments (panel A). An intracoronary injection of 0.5 mg glyc-
eryl trinitrate quickly relieved this bead-like vasospasm (panel B). An
acetylcholine provocation test was carried out seven days later. All
coronary vasodilating drugs were discontinued more than 24 hours
before the examination. Repeated coronary angiography revealed no
significant vasospasm in any coronary artery. Intracoronary injection
of 50 µg acetylcholine into the left coronary artery caused diffuse and
severe vasospasm in many segments, but could not reproduce the
bead-like vasospasm (panel C). Again, an intracoronary injection of
glyceryl trinitrate quickly relieved the vasospasm (panel D).
To the best of our knowledge, this is the first published report of a
patient with bead-like vasospasm, and it suggests that the acetylcho-
line provocation test does not always reproduce the clinical
vasospasm. How this mysterious form of vasospasm occurs remains
unknown.
S Kurisu
I Inoue
T Kawagoe
skurisu@nifty.com
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